[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Equilyse [@equilyse1](/creator/twitter/equilyse1) on x XXX followers Created: 2025-07-18 11:32:20 UTC $ABT: Abbott Labs reported strong first half 2025 results, with XXX% sales growth ex-COVID testing and double-digit EPS growth. Medical Devices, especially Diabetes Care—with FreeStyle Libre sales up XXXX% to $XXX billion—and Electrophysiology are key growth drivers. Emerging markets are also booming, with EPD surpassing $X billion in quarterly sales, fueled by biosimilar expansion. Diagnostics faces $XXX million headwinds from COVID testing decline and China's VBP. However, Abbott is optimistic about growth acceleration in 2026, driven by new products. CRM is experiencing a resurgence, with AVEIR leadless pacemaker driving XX% growth this quarter. Abbott is actively pursuing strategic M&A in diagnostics and devices, while also innovating in structural heart—Tendyne mitral valve received FDA approval. The company is also addressing infant formula litigation, standing by product safety. $ABT #earnings #medtech #diabetes  XX engagements  **Related Topics** [drivers](/topic/drivers) [eps](/topic/eps) [$abt](/topic/$abt) [abbott laboratories](/topic/abbott-laboratories) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/equilyse1/status/1946171174557192696)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Equilyse @equilyse1 on x XXX followers
Created: 2025-07-18 11:32:20 UTC
$ABT: Abbott Labs reported strong first half 2025 results, with XXX% sales growth ex-COVID testing and double-digit EPS growth. Medical Devices, especially Diabetes Care—with FreeStyle Libre sales up XXXX% to $XXX billion—and Electrophysiology are key growth drivers. Emerging markets are also booming, with EPD surpassing $X billion in quarterly sales, fueled by biosimilar expansion.
Diagnostics faces $XXX million headwinds from COVID testing decline and China's VBP. However, Abbott is optimistic about growth acceleration in 2026, driven by new products. CRM is experiencing a resurgence, with AVEIR leadless pacemaker driving XX% growth this quarter.
Abbott is actively pursuing strategic M&A in diagnostics and devices, while also innovating in structural heart—Tendyne mitral valve received FDA approval. The company is also addressing infant formula litigation, standing by product safety. $ABT #earnings #medtech #diabetes
XX engagements
Related Topics drivers eps $abt abbott laboratories stocks healthcare